The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 13, 2018
Filed:
Mar. 15, 2013
Applicants:
Daniel C. Maneval, San Diego, CA (US);
H. Michael Shepard, San Diego, CA (US);
Curtis B. Thompson, San Diego, CA (US);
Inventors:
Daniel C. Maneval, San Diego, CA (US);
H. Michael Shepard, San Diego, CA (US);
Curtis B. Thompson, San Diego, CA (US);
Assignee:
Halozyme, Inc., San Diego, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/48 (2006.01); A61K 31/56 (2006.01); A61K 31/7068 (2006.01); A61K 31/337 (2006.01); A61K 38/47 (2006.01); A61K 31/37 (2006.01); A61K 31/42 (2006.01); A61K 31/573 (2006.01); A61K 31/706 (2006.01); A61K 31/7076 (2006.01); A61K 31/7088 (2006.01); C12N 9/06 (2006.01); C12N 9/26 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 47/60 (2017.01); A61K 47/56 (2017.01); A61K 47/64 (2017.01);
U.S. Cl.
CPC ...
A61K 31/337 (2013.01); A61K 9/0019 (2013.01); A61K 31/37 (2013.01); A61K 31/42 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 31/7076 (2013.01); A61K 31/7088 (2013.01); A61K 38/47 (2013.01); A61K 45/06 (2013.01); A61K 47/48215 (2013.01); A61K 47/48284 (2013.01); A61K 47/56 (2017.08); A61K 47/60 (2017.08); A61K 47/643 (2017.08); C12N 9/003 (2013.01); C12N 9/2474 (2013.01); C12Y 105/01003 (2013.01); C12Y 302/01035 (2013.01);
Abstract
Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.